Janus kinase inhibitors alter NK cells phenotype and inhibit their antitumor capacity.

JAKi have a phenotypic and functional impact on NK cells activation and impair their antitumor activity with a variable impact depending on the JAKi. It remains an open question whether this mechanism can explain the increased tumor risk observed with TOFA.